Proton magnetic resonance spectroscopic imaging studies in patients with newly diagnosed partial epilepsy.
OBJECTIVE
To assess whether the N-acetyl aspartate (NAA) to creatine ratio (NAA/Cr) is abnormally low at the onset of epilepsy and whether successful treatment of seizures with antiepileptic drugs is sufficient for normalization of NAA/Cr.


METHODS
Proton magnetic resonance spectroscopic imaging (1H-MRSI) was used to measure NAA/Cr in temporal lobes of eight patients with newly diagnosed epilepsy before or soon after starting medication. Six patients had follow-up 1H-MRSI examinations 7 months later. Clinical pattern of the seizures and the EEG findings suggested partial seizures in all and TLE in five patients. None of the patients had lesional epilepsy according to magnetic resonance imaging.


RESULTS
Initial 1H-MRSI of the temporal lobes showed significantly low NAA/Cr values in five of eight patients. Five of six patients who had follow-up 1H-MRSI were seizure-free after using medication; the remaining patient did not take medication and continued to experience occasional auras. Wilcoxon rank sign comparison of NAA/Cr on initial 1H-MRSI examination and follow-up 1H-MRSIs showed no significant difference (Z = 135, p = 0.893, 2-tailed) for five seizure-free patients.


CONCLUSIONS
Neuronal dysfunction is present at an early stage of the epileptic process. NAA/Cr recovery in seizure-free patients controlled with antiepileptic drugs is less evident, compared with successful surgical treatment. Thus, absence of seizures is not necessarily coupled with NAA/Cr improvement and observed variable response warrants further investigation.
Li
L M
LM
Department of Neurology and Neurosurgery and the Montreal Neurological Institute and Hospital, McGill University, Montreal, Quebec, Canada.
Dubeau
F
F
Andermann
F
F
Arnold
D L
DL
D000328:Adult; D000927:Anticonvulsants / Q000494:pharmacology / Q000627:therapeutic use; D001224:Aspartic Acid / Q000031:analogs & derivatives / Q000032:analysis; D002220:Carbamazepine / Q000494:pharmacology / Q000627:therapeutic use; D003401:Creatine / Q000032:analysis; D004828:Epilepsies, Partial / Q000175:diagnosis* / Q000188:drug therapy / Q000378:metabolism; D004833:Epilepsy, Temporal Lobe / Q000175:diagnosis / Q000188:drug therapy / Q000378:metabolism; D005260:Female; D007839:Functional Laterality; D006801:Humans; D009682:Magnetic Resonance Spectroscopy; D008297:Male; D009474:Neurons / Q000378:metabolism; D013702:Temporal Lobe / Q000737:chemistry / Q000378:metabolism
D000927:Anticonvulsants; D001224:Aspartic Acid; D002220:Carbamazepine; C000179:N-acetylaspartate; D003401:Creatine